NASDAQ:CPRX

Catalyst Pharmaceuticals Stock Insider Trading

Healthcare > Biotechnology

Buy CPRX

*Your capital is at risk

$31.27

+0 (+0%)

At Close: Jun 02, 2026

Catalyst Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 66.70. In total, the insiders bought 1.61M and sold 220.4K CPRX shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	66.70
● Buy	1.61M shares
● Sell	220.4K shares
79% Buy Activity Moderate Positive Correlation
Buy Signal High Confidence Jun 01, 2026 Analysis Breakdown: Strongly supported by a very high Insider Power Score of 66.7. Partially supported by a positive historical correlation. Confidence increased due to high data reliability score of 100. Supported by overwhelming buy-side pressure (79% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Dec 29, 2025 Buy	Restricted Stock Units M-Exempt	Denkhaus Donald A Director	Director	1 334 Value: $32.1K
Dec 29, 2025 Buy	Restricted Stock Units M-Exempt	Elsbernd Brian Chief Compliance/legal Officer	Officer	6 667 Value: $160.4K
Dec 29, 2025 Buy	Common Stock, par value $0.001 per share M-Exempt	Elsbernd Brian Chief Compliance/legal Officer	Officer	6 667 Value: $160.4K
Dec 29, 2025 Sell	Common Stock, par value $0.001 per share F-InKind	Elsbernd Brian Chief Compliance/legal Officer	Officer	2 623 Value: $0
Dec 29, 2025 Buy	Restricted Stock Units M-Exempt	Miller Steve Chief Op. & Scientific Officer	Officer	14 000 Value: $336.8K
Dec 29, 2025 Buy	Common stock, par value $0.001 per share M-Exempt	Miller Steve Chief Op. & Scientific Officer	Officer	14 000 Value: $336.8K
Dec 29, 2025 Buy	Restricted Stock Units M-Exempt	Harper Molly Director	Director	1 334 Value: $32.1K
Dec 12, 2025 Sell	Common stock, par value $0.001 per share S-Sale	Harper Molly Director	Director	4 473 Value: $106.2K
Dec 12, 2025 Sell	Common stock, par value $0.001 per share S-Sale	Harper Molly Director	Director	15 527 Value: $360.2K
Dec 12, 2025 Buy	Common stock, par value $0.001 per share M-Exempt	Harper Molly Director	Director	20 000 Value: $115.6K
Dec 12, 2025 Buy	Options to purchase common stock M-Exempt	Harper Molly Director	Director	20 000 Value: $115.6K
Dec 12, 2025 Sell	Common stock, par value $0.001 per share S-Sale	Harper Molly Director	Director	6 746 Value: $155.6K
Dec 08, 2025 Buy	Common Stock, par value $0.001 per share M-Exempt	Sundaram Preethi Chief Strategy Officer	Officer	6 855 Value: $158.8K
Dec 08, 2025 Buy	Restricted Stock Units M-Exempt	Denkhaus Donald A Director	Director	1 413 Value: $32.7K
Dec 08, 2025 Buy	Common Stock, par value $0.001 per share M-Exempt	Denkhaus Donald A Director	Director	1 413 Value: $32.7K
Dec 08, 2025 Buy	Restricted Stock Units M-Exempt	Sundaram Preethi Chief Strategy Officer	Officer	6 855 Value: $158.8K
Dec 08, 2025 Buy	Restricted Stock Units M-Exempt	Harper Molly Director	Director	1 413 Value: $32.7K
Dec 08, 2025 Buy	Restricted Stock Units M-Exempt	Mcenany Patrick J Chairman Of Board Of Directors	CEO / President	3 534 Value: $81.8K
Dec 08, 2025 Buy	Common Stock, par value $0.001 per share M-Exempt	Mcenany Patrick J Chairman Of Board Of Directors	CEO / President	3 534 Value: $81.8K
Dec 08, 2025 Buy	Common Stock, par value $0.001 per share M-Exempt	Del Carmen Jeffrey Chief Commercial Officer	Officer	8 039 Value: $186.2K
Dec 08, 2025 Buy	Common Stock, par value $0.001 per share M-Exempt	Thompson Tamar Director	Director	1 413 Value: $32.7K
Dec 08, 2025 Buy	Restricted Stock Units M-Exempt	Thompson Tamar Director	Director	1 413 Value: $32.7K
Dec 08, 2025 Buy	Common Stock, par value $0.001 per share M-Exempt	Tierney David S Director	Director	1 413 Value: $32.7K
Dec 08, 2025 Sell	Common Stock, par value $0.001 per share F-InKind	Elsbernd Brian Chief Compliance/legal Officer	Officer	2 780 Value: $0
Dec 08, 2025 Buy	Restricted Stock Units M-Exempt	Miller Steve Chief Op. & Scientific Officer	Officer	11 873 Value: $275.0K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT CATALYST PHARMACEUTICALS

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develop...

Read Full Profile Here